BCL2L1 and neoplasm: Specific critical components, including polo-like kinase 1 (PLK1), observed inhibition of mitosis progression kinase cdc25c in Western blot analysis; moreover, gene expression of specific proteins including downregulation of Bcl-xl, cyclin-D, cyclin-e, and COX-2 and upregulation of c-myc, BAX, and caspase-3 was reported, which indicates that ceAF is performing response mediated therapy against tumor cells.